New Lifetime High Reached: Thermo Fisher Scientific (TMO)
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Trade-Ideas LLC identified
(
) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Thermo Fisher Scientific as such a stock due to the following factors:
- TMO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $213.7 million.
- TMO has traded 1,353 shares today.
- TMO is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in TMO with the Ticky from Trade-Ideas. See the FREE profile for TMO NOW at Trade-Ideas
More details on TMO:
Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The stock currently has a dividend yield of 0.5%. TMO has a PE ratio of 28.1. Currently there are 14 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for Thermo Fisher Scientific has been 1.7 million shares per day over the past 30 days. Thermo Fisher Scientific has a market cap of $52.5 billion and is part of the health care sector and health services industry. The stock has a beta of 1.01 and a short float of 0.7% with 1.81 days to cover. Shares are up 6.9% year-to-date as of the close of trading on Wednesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Thermo Fisher Scientific as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 16.6%. Since the same quarter one year prior, revenues rose by 29.6%. Growth in the company's revenue appears to have helped boost the earnings per share.
- THERMO FISHER SCIENTIFIC INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, THERMO FISHER SCIENTIFIC INC increased its bottom line by earning $4.70 versus $3.49 in the prior year. This year, the market expects an improvement in earnings ($7.33 versus $4.70).
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Life Sciences Tools & Services industry. The net income increased by 75.7% when compared to the same quarter one year prior, rising from $342.10 million to $601.20 million.
- Net operating cash flow has increased to $953.70 million or 30.91% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 16.65%.
- You can view the full Thermo Fisher Scientific Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
null